EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma

Yue Ma iD, Ru Jia iD, Mengjiao Fan iD, Guochao Deng, Tieqiang Liu, Yanrong Wang iD, Yue Li, Nan Zhang, Fang Pang iD, Yue Shi, Yaoyue Zhang, Yuting Pan iD und 3 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Yue Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Muscle, Skeletal, Sarcopenia. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Wu Jieping Medical Foundation, Beijing Dingyi Public Welfare Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study investigated relationships between the skeletal muscle index (SMI) and the tumor immune microenvironment (TIME), peripheral immune phenotypes, and serum biomarkers in advanced pancreatic ductal adenocarcinoma (PDAC) and evaluated the prognostic significance of these parameters.

Methods

A retrospective analysis of 119 advanced PDAC patients was performed. Sarcopenia was diagnosed using sex‐specific SMI cut‐offs from baseline L3‐level computed tomography (CT) images. The TIME was characterized by multiplex immunofluorescence (mIF; n = 31), peripheral immunity by flow cytometry, and serum biomarkers by routine testing. Associations with SMI were examined using Spearman correlation; prognostic relevance was assessed using Cox proportional hazards models.

Results

Sarcopenia (56/119, 47.1%) was associated with shorter progression‐free survival (PFS) (8.83 vs. 12.03 months, p = 0.016) and overall survival (OS) (10.20 vs. 17.33 months, p = 0.014). SMI correlated most strongly with stromal CD8 + T cells ( ρ = 0.52), stromal total T cells ( ρ = 0.52), and stromal M2 macrophages ( ρ = 0.50) in the TIME; with circulating Th2‐like cells ( ρ = −0.58) and CD4 + memory T cells ( ρ = 0.45) peripherally; and with hemoglobin ( ρ = 0.32) among serum markers. In multivariable Cox regression, stromal CD4 + Treg percentage independently predicted OS (hazard ratio [HR] = 7.60, 95% confidence interval [CI] 1.60–36.22, p = 0.011), stromal CD56dim natural killer (NK)‐cell density predicted PFS (HR = 1.015, 95% CI 1.001–1.028, p = 0.031), and the lymphocyte‐to‐monocyte ratio (LMR) predicted both PFS (HR = 0.86, p = 0.023) and OS (HR = 0.83, p = 0.009). No peripheral lymphocyte subset reached prognostic significance.

Conclusion

SMI is broadly associated with local and systemic immune phenotypes in advanced PDAC. Stromal CD4 + regulatory T cells (Tregs), CD56dim NK cells, and LMR carry independent prognostic information and may complement body‐composition assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsMuscle, SkeletalSarcopeniaHumansFemaleMaleTumor MicroenvironmentRetrospective StudiesPrognosisAgedMiddle AgedBiomarkers, Tumor

Stichwörter der Autor:innen

lymphocyte‐to‐monocyte ratiopancreatic ductal adenocarcinomasarcopeniaskeletal muscle indextumor immune microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China.
  • Medical School of Chinese PLA, Beijing, China.
  • Senior Department of Hematology, Chinese PLA General Hospital, Beijing, China.
  • Integrated Daytime Treatment Ward, Peking University People's Hospital, Beijing, China.
  • School of Medicine, Nankai University, Tianjin, China.
  • Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.

ORCID-Profile: Yue Ma, Ru Jia, Mengjiao Fan, Yanrong Wang, Fang Pang, Yuting Pan, Zhikuan Wang, Guanghai Dai

Förderung

  • National Natural Science Foundation of China
  • Wu Jieping Medical Foundation
  • Beijing Dingyi Public Welfare Foundation

Zitieren

APA

Ma, Y., Jia, R., Fan, M., Deng, G., Liu, T., Wang, Y., Li, Y., Zhang, N., Pang, F., Shi, Y., Zhang, Y., Pan, Y., Wang, Q., Wang, Z., & Dai, G. (2026). Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.72378

Vancouver

Ma Y, Jia R, Fan M, Deng G, Liu T, Wang Y, et al. Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Medicine. 2026. doi:10.1002/cam4.72378

BibTeX
@article{Ma2026,
  author = {Ma, Yue and Jia, Ru and Fan, Mengjiao and Deng, Guochao and Liu, Tieqiang and Wang, Yanrong and Li, Yue and Zhang, Nan and Pang, Fang and Shi, Yue and Zhang, Yaoyue and Pan, Yuting and Wang, Qi and Wang, Zhikuan and Dai, Guanghai},
  title = {Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72378}
}
Kostenlos starten →